Vanda Pharmaceuticals (NASDAQ:VNDA) Earns Overweight Rating from Cantor Fitzgerald
Cantor Fitzgerald restated their overweight rating on shares of Vanda Pharmaceuticals (NASDAQ:VNDA – Free Report) in a research report sent to investors on Wednesday morning,Benzinga reports. They currently have a $13.00 target price on the biopharmaceutical company’s stock. Cantor Fitzgerald also issued estimates for Vanda Pharmaceuticals’ FY2025 earnings at ($1.55) EPS and FY2025 earnings at […]
Cantor Fitzgerald restated their overweight rating on shares of Vanda Pharmaceuticals (NASDAQ:VNDA – Free Report) in a research report sent to investors on Wednesday morning,Benzinga reports. They currently have a $13.00 target price on the biopharmaceutical company’s stock. Cantor Fitzgerald also issued estimates for Vanda Pharmaceuticals’ FY2025 earnings at ($1.55) EPS and FY2025 earnings at […]
